Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

ENABLE: an engine for European antibacterial drug discovery and development

ENABLE is an antibacterial drug discovery and development consortium formed as a public–private partnership in 2014 as part of the Innovative Medicines Initiative (IMI) New Drugs for Bad Bugs (ND4BB) programme. With the project soon ending, here we provide a brief overview and reflect on its achievements, strengths and weaknesses.
  1. Marie Olliver

    1. Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Laura Griestop

    1. BIOCOM, Berlin, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Diarmaid Hughes

    1. Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Anna Karin Belfrage

    1. Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Johan Gising

    1. Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  6. Pawel Baranczewski

    1. Department of Pharmacy, Uppsala University Drug Optimization and Pharmaceutical Profiling and SciLifeLab Drug Discovery and Development Platform, Uppsala University, Uppsala, Sweden.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  7. Carina Vingsbo Lundberg

    1. Bacteria, Parasites & Fungi, Statens Serum Institut, Copenhagen, Denmark.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  8. Anders Karlén

    1. Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Despite an urgent need for new antibiotics, many large pharmaceutical companies have abandoned antibiotic research because antibiotic development is scientifically challenging and economically unprofitable. Public–private partnerships could play a key role in facilitating the mobilization of resources from various stakeholders to accelerate the development of new antibiotics, and here we discuss one such partnership: ENABLE (European Gram-Negative Antibacterial Engine). The 7-year project was launched by the Innovative Medicines Initiative (IMI), a joint initiative between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA), with the goal to replenish the pipeline of antibiotics for systemic Gram-negative infections, targeting the key pathogens Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 20, 407-408 (2021)

doi: https://doi.org/10.1038/d41573-021-00074-y

Acknowledgements

The authors thank all colleagues and partners involved in ENABLE (Supplementary Table 2), and gratefully acknowledge PMC members and platform leads for providing valuable insights. The authors wish to thank members of the Consortium Management Office, C. Nilsson, E. Bacqué, N. Pearson, R. Neal, F. Deroose, A. Lobell, N. Murillo, L. Löwenau and C. Robijns, for their contributions as well as critical reading of the manuscript. R. Stavenger is acknowledged for his tremendous efforts in helping to set up ENABLE and ensuring its smooth running in the early years. The authors have received support from the IMI Joint Undertaking under grant agreement no. 115583, resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme and EFPIA companies’ in-kind contributions.

Disclaimer

The views expressed in this article are the views of the authors and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.

Supplementary Information

  1. Supplementary information

Competing Interests

The authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links